Today is Friday, Oct. 20, 2017

Cancer Institute

William Barrett, MDWilliam Barrett, MD

Director, University of Cincinnati Cancer Institute
Chairman and Professor, Department of Radiation Oncology
Medical Director, UC Health Barrett Cancer Center

William Barrett, MD, is director of the University of Cincinnati (UC) Cancer Institute, professor and chair of the department of radiation oncology at the UC College of Medicine and medical director of the UC Health Barrett Cancer Center.

Dr. Barrett received his undergraduate degree from the University of Virginia and his medical degree from UC. His training included an internship in general surgery at UC followed by residency in radiation oncology at UC and a fellowship in brachytherapy at Memorial Sloan-Kettering Cancer Center.

He has been on the faculty at UC since 1992 and has experience in treating patients with most types of cancers. Dr. Barrett 's areas of particular interest include cancer of the prostate, cancer of the head and neck and the use of radiation seeds as well as external radiation therapy for a number of cancers. He focuses on cancer education for the general public as well as physicians in the greater Cincinnati area and has organized a number of educational conferences in addition to being very involved in medical student and resident education at the university.


Thomas Herzog, MDThomas Herzog, MD

Clinical Director, University of Cincinnati Cancer Institute
Professor, Department of Obstetrics and Gynecology

Thomas Herzog, MD, is clinical director of the UC Cancer Institute and is professor of obstetrics and gynecology at the UC College of Medicine.

Dr. Herzog graduated from the UC College of Medicine in 1986. He completed his residency at Good Samaritan Hospital in Cincinnati in 1990 and a fellowship in gynecologic oncology at the Washington University School of Medicine in St. Louis in 1993 before becoming a faculty member at Washington University and then director of its gynecologic oncology fellowship program. In 2004, he became the director of the division of gynecologic oncology at Columbia University in New York.

Herzog is a National Institutes of Health- and American Cancer Society-funded researcher who has published more than 200 peer-reviewed manuscripts. He has served as a member of several professional societies including the American College of Surgeons, for which he is also on the elected board of governors, the American Board of Obstetrics and Gynecology and the American Society for Colposcopy and Cervical Pathology, among others. Herzog is also editor-in-chief of Gynecologic Oncology Research and Practice and serves on the editorial boards for a number of other peer-reviewed journals.


Shuk-Mei,-Ho.jpgShuk-Mei Ho, PhD

Chief Scientific Officer, University of Cincinnati Cancer Institute

Shuk-Mei Ho, PhD, Jacob G. Schmidlapp Professor and Chair in the Department of Environmental Health, Hayden Family Endowed Chair and director of the Cincinnati Cancer Center, received her PhD from the University of Hong Kong. She is internationally recognized for her expertise in the role of hormones and endocrine disruptors on disease development including tumor formation in the prostate, ovary, endometrium and breast. The 2015 recipient of the University of Cincinnati 's Rieveschl Award for Distinguished Scientific Research, she has made major contributions to our understanding of the impact of heavy metals, oxidative stress and inflammation on carcinogenesis; the discovery of biomarkers for cancer detection and patient classification, and mechanism-based drug development.

Dr. Ho 's work explores the developmental origins of disease susceptibility by applying epigenetics to epidemiological studies, thereby addressing two important challenges of research in environmental exposure and human health: multiple exposures at various developmental stages and the trans-generational effects of exposure.


Guan Jun-linJun-Lin Guan, PhD

Basic Science Research Director, University of Cincinnati Cancer Institute

Jun-Lin Guan, PhD, Francis Brunning Endowed Chair and Professor of Cancer Biology, received his PhD at the University of California at San Diego in 1987. After postdoctoral training at the Center for Cancer Research at the Massachusetts Institute of Technology, Dr. Guan joined Cornell University faculty as an assistant professor in 1991 where he became a full professor in 2001. He became a faculty member at the University of Michigan Medical School in 2006, and finally joined the UC faculty in 2014.

Dr. Guan 's research centers on the mechanisms of cell signaling in biological processes and how disruption of the normal signaling pathways leads to cancer and other diseases. He is world renowned for his work on focal adhesion kinase (FAK), an important cytoplasmic signaling enzyme that impacts a wide range of normal physiology and pathology.


kenKen Greis, PhD

Core Facilities Director, University of Cincinnati Cancer Institute

Ken Greis, PhD, is a professor in the Department of Cancer Biology. He received his PhD from the University of Kentucky in 1991 and completed post-doctoral training at Johns Hopkins School of Medicine in 1993 and the University of Alabama at Birmingham in 1996.

Dr. Greis is in charge of the UC Proteomics Laboratory within the Department of Cancer Biology. Proteomics is the large-scale analysis of protein expression patterns. Along with functional genomics, proteomics is now an established tool for investigators to better understand the molecular events underlying many biological processes. The laboratory is equipped with protein separation and mass spectrometry equipment as well as trained personnel to perform comparative analyses of complex protein mixtures and to identify the differentially-expressed proteins.

Dr. Greis ' research is dedicated toward integrating mass spectrometry-based technology to understand biological systems. He collaborates with many investigators across the University of Cincinnati, Cincinnati Children 's Hospital Medical Center and outside institutions and businesses. Currently, his two primary research focuses are in the area of quantitative phosphorylation profiling and the use of mass spectrometry for enzyme assays and high throughput inhibitor screening.


MorrisJohn-with-lab-coat.jpgJohn Morris, MD, PhD

Translational Research Director, University of Cincinnati Cancer Institute

John Morris, MD, PhD, is a professor in the Division of Hematology Oncology, Department of Internal Medicine, and co-director of the Lung Cancer Center within the UC Cancer Institute. He received his medical degree from the Upstate Medical Center College of Medicine and did several years of post-doctoral training at Mount Sinai Hospital. Dr. Morris completed a post-doctoral fellowship at the National Institutes of Health in 1999.

In addition to being an oncologist working with lung cancer patients, Dr. Morris oversees the Experimental Phase I Therapeutics Program. Phase I trials help physicians determine acceptable dosages and possible side-effects of new therapies. These research trials are the first step in moving tested scientific concepts from the laboratory bench to the patient; they typically include less than 50 people and are important for patients who may not have standard treatment options, as these therapies are novel and not widely available. The UC Cancer Institute is the only facility in the Tristate area with a Phase I program. Dr. Morris is also interested in immunologic strategies to treat cancer.


Wise-DraperTrisha-with-UCH-lab-coat.jpgTrisha Wise-Draper, MD, PhD

Clinical Research Director, University of Cincinnati Cancer Institute

Trisha Wise-Draper, MD, PhD, assistant professor in the Division of Hematology Oncology in the Department of Internal Medicine, received her MD/PhD from the University of Cincinnati and completed her residency at University of Cincinnati Medical Center.

Dr. Wise-Draper 's research focuses on translational mechanisms of therapeutic resistance and biomarkers in cancer, particularly head and neck cancer. Specifically, she is interested in identifying mechanisms important for immunotherapy resistance including T cell dysfunction, the role of macrophages and possible signaling pathways involved. She is also involved with the Experimental Phase I Therapeutics Program.


researcher looking through microscope and at computer screen

Educational Events

Breast Reconstruction Awareness Day
Wednesday, October 18, 2017 @ 4:30 - 6:30 p.m.

Breast Cancer Patient Conference- We See Individual Breast Cancer: You See Personalized Care
Sunday, November 4, 2017 @ 9:00 a.m.- 3:00 p.m.

Lung Cancer: Revolutionary Progress & Future Directions
Saturday, November 11, 2017 @ 8:00 a.m. - 2:00 p.m.
CME

All Events »